Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.

@article{Goldberg1998EffectOR,
  title={Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.},
  author={Dennis Ian Goldberg and Maureen Dillon and Eduardo A Slatopolsky and Bruce N. Garrett and J R Gray and Thomas C. Marbury and Marc S Weinberg and Duane G. Wombolt and Steven K Burke},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={1998},
  volume={13 9},
  pages={
          2303-10
        }
}
  • D. Goldberg, M. Dillon, +6 authors S. Burke
  • Published 1998
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
BACKGROUND Control of dietary phosphate absorption in end-stage renal disease patients is essential to prevent the deleterious sequelae of phosphorus retention. Efficacy of currently available calcium- and aluminium-containing phosphate binders is constrained by the side-effects associated with the absorption of calcium and aluminium. The current study examined the efficacy of RenaGel, a calcium- and aluminium-free, polymeric phosphate binder, in end-stage renal disease patients. METHODS… Expand
PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Lanthanum Carbonate as a First‐Line Phosphate Binder: The “Cons”
TLDR
The experience with aluminum hydroxide suggests caution regarding the long‐term use of another metal‐based agent that displays enhanced absorption in the uremic state and progressive tissue accumulation. Expand
Efficacy, Tolerability, and Safety of Lanthanum Carbonate in Hyperphosphatemia: A 6-Month, Randomized, Comparative Trial versus Calcium Carbonate
TLDR
This 6-month study demonstrates that serum phosphate control with lanthanum carbonate is similar to that seen with calcium carbonate, but with a significantly reduced incidence of hypercalcemia. Expand
Safety of New Phosphate Binders for Chronic Renal Failure
TLDR
Sevelamer, an aluminium- and calcium-free Pi binder can reduce serum phosphorus concentration and is associated with a significantly lower incidence of hypercalcaemia, while maintaining the ability to suppress parathyroid hormone production. Expand
Hyperphosphatemia and phosphate binders.
  • Jason J. Schucker, K. Ward
  • Chemistry, Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2005
TLDR
If left untreated, hyperphosphatemia can result in secondary hyperparathyroidism, renal osteodystrophy, and metastatic calcification of blood vessels and soft tissue. Expand
The safety of phosphate binders.
TLDR
In patients with end stage renal disease, standard dialysis (three times/week) falls far short of removing adequate amounts of absorbed phosphorus; therefore, hyperphosphataemia is found in the majority of these patients. Expand
Sevelamer Hydrochloride versus Aluminum Hydroxide: Effect on Serum Phosphorus and Lipids in CAPD Patients
TLDR
Sevelamer hydrochloride is a well-tolerated alternative to calcium- or aluminum-containing phosphorus binder in the control of serum phosphorus in CAPD patients and improves the lipid profile in these patients. Expand
The safety of phosphate binders
Disturbances of mineral metabolism occur during the early stages of chronic kidney disease. As renal function worsens, excess dietary phosphorus accumulates and blood levels increase, that can beExpand
Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
TLDR
The results show that this new adsorbent might provide an alternative to conventional aluminum and calcium containing phosphate-binding agents for combating hyperphosphataemia. Expand
Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
  • N. Nagano, S. Miyata, +5 authors M. Wada
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2001
TLDR
The correlation analysis suggests that reduced serum phosphorus levels contributed to the suppression of PTG hyperplasia and resulted in the reduction of PTH levels in this animal model after the sevelamer treatment. Expand
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
TLDR
Nicotinamide may provide an alternative for controlling hyperphosphatemia and hyperparathyroidism without inducing hypercalcemia in hemodialysis patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-3 OF 3 REFERENCES
Phosphorus and protein restriction and parathyroid function in chronic renal failure.
TLDR
A direct inhibition of PTH secretion over a wide range of iCa concentration by LPD in patients with advanced CRF and mild HPT II over a three months period is demonstrated, independent of changes in plasma calcitriol levels. Expand
Are we mismanaging calcium and phosphate metabolism in renal failure?
  • C. Hsu
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1997
Secondary hyperparathyroidism and renal osteodystrophy are the consequences of abnormal calcium, phosphate, and calcitriol metabolism ensuing from renal failure. Evidence suggests that calciumExpand
Prevention of phosphate retention and hyperphosphatemia in uremia.